Application 761196

Type
BLA
Sponsor
ADC Therapeutics SA

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761196Zynlontaloncastuximab tesirine-lpyl351(a)Rx2026-08-01

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001ZYNLONTALONCASTUXIMAB TESIRINE-LPYLINJECTABLE;INJECTION10MGNoNo

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
ZYNLONTALONCASTUXIMAB TESIRINEADC Therapeutics America, Inc.af54af12-3edf-4301-8bc5-0446bc813c1d2026-06-12Warnings, Adverse reactionsExact identifier
application number: BLA761196
ndc (product): 79952-110

NDC Listings For This Application#

NDC listings for this application page 1 of 1 · 6 matching rows.

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
79952-110ZYNLONTAloncastuximab tesirineADC Therapeutics America, Inc.BLACurrent
79952-110ZYNLONTAloncastuximab tesirineADC Therapeutics America, Inc.BLACurrent
79952-110ZYNLONTAloncastuximab tesirineADC Therapeutics America, Inc.BLACurrent
79952-110ZYNLONTAloncastuximab tesirineADC Therapeutics America, Inc.BLACurrent
79952-110ZYNLONTAloncastuximab tesirineADC Therapeutics America, Inc.BLACurrent
79952-110ZYNLONTAloncastuximab tesirineADC Therapeutics America, Inc.BLACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
85144SUPPL 2026-02-24
85115SUPPL 2026-02-24
84814SUPPL 2026-01-22
84802SUPPL 2026-01-21
72398SUPPL2022-10-17
72397SUPPL2022-10-17
72317SUPPL2022-10-13
72316SUPPL2022-10-13
67576ORIG2021-05-24
67180ORIG2021-04-27
67161ORIG2021-04-23